The Global Bile Duct Cancer Market Growth Accelerated By Rising Incidence Of Bile Duct Cancer
Bile Duct Cancer Market |
The bile duct cancer market
comprises drugs for treating bile duct cancer or cholangiocarcinoma. Bile duct
cancer drugs help improve the overall survival and quality of life of patients.
With rising incidence rates of bile duct cancer globally, the demand for
effective treatment options is increasing.
The global bile duct cancer
market is estimated to be valued at US$ 235.9 Mn in 2023 and is expected to
exhibit a CAGR of 12% over the forecast period 2023 to 2030, as highlighted in
a new report published by Coherent Market Insights.
Market key trends:
Increased research and
development activites is one of the key trends driving the bile duct cancer
market growth. Several pharmaceutical companies are investing heavily in
clinical trials to develop novel targeted therapies and immunotherapies for
bile duct cancer. For instance, Incyte Corporation is developing a PD-L1
inhibitor named retifanlimab for treating advanced bile duct cancer and other
solid tumors. Positive results from ongoing phase 2 clinical trials can capture
a sizeable market share and accelerate the revenue growth of companies.
Furthermore, rising approval of new drugs will expand treatment options and
support market growth over the forecast period.
Segment Analysis
The global bile duct cancer
market is dominated by the chemotherapy sub-segment. Chemotherapy being an
effective treatment for bile duct cancer and high success rates have made it
the preferred choice of treatment among medical practitioners and patients. It
is effective in both early and advanced stages of bile duct cancer helping
destroy any remaining cancer cells post surgery.
Key Takeaways
The Global
Bile Duct Cancer Market Size is expected to witness high growth over
the forecast period of 2023 to 2030. The market is anticipated to grow at a
CAGR of 12% during the forecast period and reach a value of US$ 520.9 Mn by
2030.
Regional analysis
North America dominates the
global bile duct cancer market currently. Availability of advanced healthcare
facilities and high awareness regarding early diagnosis are some key factors
contributing to the large share of the region. Asia Pacific is expected to
witness the fastest growth over the forecast period. Growing geriatric
population, improving healthcare infrastructure and increasing healthcare
expenditure are expected to boost market growth in the region.
Key players
Key players operating in the bile
duct cancer market are Incyte Corporation, Eisai Co., Ltd., QED Therapeutics,
Inc., Agios Pharmaceuticals, Inc. These companies are focusing on developing
innovative treatment options to improve outcomes for patients. Incyte
Corporation's Pemigatinib is a selective FGFR inhibitor being evaluated in
ongoing clinical trials for bile duct cancer. Eisai Co., Ltd. is engaged in
research on Erdafitinib which acts on FGFR.
Get More Insights Here
https://www.newsstatix.com/bile-duct-cancer-market-size-share-growth-outlook-2023/
Comments
Post a Comment